Rachelle Doody, Roche Pharmaceuticals, Basel, Switzerland

Rachelle Doody

Rachelle Doody, MD, PhD, is the global head of neurodegeneration and franchise head in product development at Roche Pharmaceuticals and its subsidiary, Genentech. As part of Roche, she oversees late stage development of drugs for Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis. Doody specialised in neurology and psychiatry and trained at Baylor College of Medicine and McGill University. While at Baylor College of Medicine, she founded and directed the Alzheimer’s disease and Memory Disorders Center and was the Effie Marie Cain Chair in Alzheimer’s Disease Research. Doody has served on steering committees for the National Institutes of Health-funded Alzheimer’s Disease Cooperative Study, Alzheimer’s Disease Neuroimaging Initiative, and the executive committee for the Alzheimer’s Therapeutic Research Institute. For over 25 years, Dr Doody has worked with biotechnology and pharmaceutical companies in the design and execution of trials for cognitive and behavioral treatment of Alzheimer’s disease. Doody has published over 200 original articles in this field. In her role as a practicing neurologist, Doody was elected to the Best Doctors in America list from 1996 to 2016. She has received many awards from professional and civic groups, including the Distinguished Alumni Award from Rice University in 2009 and the Distinguished Faculty Award from Baylor College of Medicine in 2011.

« Go Back

Supporting Publications
Organised by
  • Elsevier
  • TLN
  • the lancet
Sponsored by